Crossmark Global Holdings Inc. Invests $596,000 in Omnicell, Inc. (OMCL) Stock
Crossmark Global Holdings Inc. purchased a new position in Omnicell, Inc. (NASDAQ:OMCL) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,673 shares of the company’s stock, valued at approximately $596,000.
A number of other institutional investors also recently made changes to their positions in OMCL. California Public Employees Retirement System increased its stake in shares of Omnicell by 4.2% during the second quarter. California Public Employees Retirement System now owns 81,200 shares of the company’s stock valued at $3,500,000 after buying an additional 3,300 shares during the period. Bank of America Corp DE increased its stake in shares of Omnicell by 79.7% during the first quarter. Bank of America Corp DE now owns 202,466 shares of the company’s stock valued at $8,231,000 after buying an additional 89,817 shares during the period. Oak Ridge Investments LLC increased its stake in shares of Omnicell by 0.6% during the second quarter. Oak Ridge Investments LLC now owns 1,537,940 shares of the company’s stock valued at $66,285,000 after buying an additional 8,491 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Omnicell by 82.7% during the first quarter. Goldman Sachs Group Inc. now owns 88,926 shares of the company’s stock valued at $3,615,000 after buying an additional 40,240 shares during the period. Finally, GAM Holding AG purchased a new position in shares of Omnicell during the second quarter valued at approximately $2,866,000. 98.64% of the stock is currently owned by institutional investors and hedge funds.
In related news, Chairman Randall A. Lipps sold 10,625 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $52.00, for a total value of $552,500.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gary S. Petersmeyer sold 1,000 shares of the company’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $51.73, for a total value of $51,730.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,232 shares of company stock worth $1,569,651. 3.77% of the stock is owned by insiders.
Shares of Omnicell, Inc. (NASDAQ OMCL) opened at $47.95 on Friday. Omnicell, Inc. has a 12 month low of $31.85 and a 12 month high of $55.40. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.42. The company had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.40 earnings per share. research analysts anticipate that Omnicell, Inc. will post 0.12 EPS for the current year.
OMCL has been the topic of several research analyst reports. Dougherty & Co boosted their target price on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Craig Hallum boosted their target price on Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Cantor Fitzgerald reissued a “buy” rating and set a $47.00 target price on shares of Omnicell in a research note on Tuesday, July 25th. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Thursday, October 19th. Finally, Benchmark Co. boosted their target price on Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $54.86.
WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.watchlistnews.com/crossmark-global-holdings-inc-invests-596000-in-omnicell-inc-omcl-stock/1709065.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.